viewOpen Orphan PLC

Open Orphan PLC targeting 'value creation and rapid scale-up'

Proactive Research analyst Emma Ulker discusses the opportunity with Open Orphan PLC (LON:ORPH).

She says the firm's targeting value creation and rapid scale-up via acquisitions in the orphan and rare drugs market - a space which is growing at around 11% a year.

Ulker adds they're looking to combine a number of smaller consultancies focused on the orphan and rare disease space, extracting both top-line and cost synergies.

Quick facts: Open Orphan PLC

Price: 6.35 GBX

Market: AIM
Market Cap: £16.17 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...



Full interview: Open Orphan confirms hVIVO deal is done

Cathal Friel, CEO of Open Orphan announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like. News here on the Genomic Database and how Friel expects hVIVO to make a profit. Confirmation too on the slight musical chairs within...

6 days, 14 hours ago


Holding(s) in Company

12 hours, 29 minutes ago

Holding(s) in Company

1 day, 10 hours ago

Euronext Growth Dublin Notice

1 day, 18 hours ago

Offer Wholly Unconditional

4 days, 19 hours ago

Schedule One Update

5 days, 12 hours ago

2 min read